期刊
PHARMACOLOGICAL REVIEWS
卷 61, 期 3, 页码 373-393出版社
AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/pr.109.001560
关键词
-
资金
- Swedish Medical Research Council
- Swedish Heart-Lung Foundation
- Swedish Diabetes Foundation
- Professor Nanna Svartz Foundation,
- Magn. Bergvalls Foundation
- Novo-Nordisk Foundation
- Hedlund Foundation
- Foundation for Old Servants
- Karolinska Institutet
Agonists directed against the alpha and gamma isoforms of the peroxisome proliferator-activated receptors (PPARs) have become important for the respective treatment of hypertriglyceridemia and insulin resistance associated with metabolic disease. PPAR delta is the least well characterized of the three PPAR isoforms. Skeletal muscle insulin resistance is a primary risk factor for the development of type 2 diabetes. There is increasing evidence that PPAR delta is an important regulator of skeletal muscle metabolism, in particular, muscle lipid oxidation, highlighting the potential utility of this isoform as a drug target. In addition, PPAR delta seems to be a key regulator of skeletal muscle fiber type and a possible mediator of the adaptations noted in skeletal muscle in response to exercise. In this review we summarize the current status regarding the regulation, and the metabolic effects, of PPAR delta in skeletal muscle.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据